STOCK TITAN

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

AIM ImmunoTech announced that its CEO, Thomas K. Equels, will participate in two upcoming investor conferences. The first event, the Healthcare Company Showcase hosted by Alliance Global Partners, will take place on May 21, 2024, at 3:20 PM ET. The second event, LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar, is scheduled for May 22, 2024, at 3:40 PM ET. Both presentations will be webcast live and accessible via the Events page on AIM ImmunoTech's Investor section of their website.

Positive
  • CEO participation in two investor conferences can increase visibility for AIM.
  • Live webcasts allow broader access to the company's presentations.
Negative
  • No new financial or clinical data was provided in the announcement.
  • Participation in conferences alone may not significantly impact stock performance without substantial updates.

OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences.

Details for the presentations are as follows:

Event: Healthcare Company Showcase hosted by Alliance Global Partners
Date and Time: Tuesday, May 21, 2024, at 3:20 PM ET
Webcast Link

Event: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Date and Time: Wednesday, May 22, 2024, at 3:40 PM ET
Webcast Link

Live webcasts of the presentations will be accessible on the Events page of the Investors section of the Company’s website, aimimmuno.com.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on XLinkedIn, and Facebook.


FAQ

When will AIM ImmunoTech's CEO present at the Healthcare Company Showcase?

Thomas K. Equels will present at the Healthcare Company Showcase on May 21, 2024, at 3:20 PM ET.

What is the date and time for AIM ImmunoTech's presentation at the LIVE! with Webull Corporate Connect?

The presentation is scheduled for May 22, 2024, at 3:40 PM ET.

Where can I access the live webcasts of AIM ImmunoTech's investor conference presentations?

Live webcasts of the presentations will be accessible on the Events page of AIM ImmunoTech's Investor section on their website.

AIM ImmunoTech Inc.

NYSE:AIM

AIM Rankings

AIM Latest News

AIM Stock Data

14.78M
63.71M
8.57%
13.22%
0.81%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
OCALA